• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    芝

    芝加哥大学医学中心

    University of Chicago Medical Center
    院校EST. 1899
    2,859论文总数
    9.6万引用总数

    The University of Chicago Medical Center (UChicago Medicine) is a nationally ranked academic medical center located in Hyde Park on the South Side of Chicago. It is the flagship campus for The University of Chicago Medicine system and was established in 1898. Affiliated with and located on The University of Chicago campus, it also serves as the teaching hospital for Pritzker School of Medicine. Primary medical facilities on campus include the Center for Care and Discovery, Bernard A. Mitchell Hospital, and Comer Children's Hospital.In 2019, U.S. News and World Report ranked UChicago Medicine the second-best hospital in both Chicago and Illinois behind Northwestern Memorial Hospital.S.S.

    论文量&引用量时间轴

    机构学者

    论文(2859)

    年份
    起
    –
    止
    排序
    1A Case of Heart Transplant after Bartonella Henselae Infective Endocarditis Associated with an Implantable Cardioverter-Defibrillator
    Michael Z Chen, Kritos P Vasiloudes, John M Flores, Joseph P Gaut, Michael T Czapka

    To our knowledge, only one case of acute Bartonella henselae infective endocarditis treated with heart transplantation as salvage therapy has been published. There is a paucity of literature on management of Bartonella henselae endocarditis in the pre-transplant and post-transplant periods. A 63-year-old Caucasian man with past medical history of heart failure with reduced ejection fraction with implantable cardioverter-defibrillator and HeartMate II left-ventricular assist device was diagnosed with presumptive Bartonella henselae infective endocarditis after presenting with infectious glomerulonephritis. He successfully underwent heart transplant with device removal and was able to discontinue chronic suppressive doxycycline therapy without recurrence of infective endocarditis. There remains a paucity of literature on Bartonella henselae endocarditis treated with orthotopic heart transplant and this case report represents the second known case. Our case is also unique in that the patient had endocarditis associated with an implantable cardioverter-defibrillator. We hope it may serve as another resource to guide diagnosis and treatment of Bartonella henselae endocarditis associated with or without cardiac hardware, as well as monitoring for recurrent disease after transplant.

    2026SN Comprehensive Clinical Medicine(2026)引用:12
    引用
    AI阅读
    加入学术空间
    2Radiation Segmentectomy for Treatment of Hepatic Oligometastases Greater Than 3 Cm
    Qian Yu, Ali Ahmed,Wali Badar, Daniel Kwak, Aaron William Lyon, Yating Wang, Carla Harmath,Mikin Patel, Divya Kumari, Thuong Van Ha,Osman Ahmed

    PURPOSE:The effectiveness of percutaneous thermoablation as curative treatment of hepatic oligometastases greater than 3 cm can be limited by the ability to achieve adequate ablation coverage. Radiation segmentectomy (RS) using yttrium-90 (Y90) microspheres is an established treatment and potentially curative for hepatocellular carcinoma (HCC) up to 8 cm. This study evaluates the safety and effectiveness of RS for secondary liver tumors larger than 3 cm. METHODS:A retrospective review at a single institution was performed from December 2017 to February 2024 to include patients treated with transarterial radioembolization (TARE) for liver metastases using glass Y90 microspheres. RS was defined as a target dose > 200 Gy to no more than two liver segments. The following outcomes were retrieved: overall survival (OS), radiologic response, progression-free survival (PFS), adverse events, and 3-month serum toxicity. RESULTS:A total of 14 patients (mean age: 64.2 ± 18.5, M:F = 5:9) with secondary liver tumors (mean diameter: 4.7 ± 1.4 cm; single hepatic lesion: 57.1 %[8/14]), including 5 colorectal cancer (35.7 %), 2 renal cell carcinoma (14.3 %), 2 uveal melanoma (14.3 %), 2 adenoid cystic carcinoma (14.3 %), 1 pancreatic adenocarcinoma (7.1 %), 1 endometrial carcinoma (7.1 %), and 1 tonsillar adenocarcinoma (7.1 %). The mean segmentectomy dose was 352.6 ± 149.1 Gy. Response rate and disease control rate were 42.9 % (6/14) and 85.7 % (12/14), respectively. The 1-yr and 3-yr target tumor response rates were 51.4 % (95 %CI: 21.9-74.8 %) and 34.2 % (95 %CI: 7.1-64.9 %), respectively, with a median PFS of 16.3 months 95 %CI: 5.4 months-not reached). The 1-yr and 3-yr OS were 80.8 % (95 %CI: 42.4-94.9 %) and 40.4 % (95 %CI: 9.8-70.2 %), respectively, with a median OS of 24.3 months (95 %CI: 8.9-not reached). One patient developed grade 3 thrombocytopenia, requiring holding of systemic treatment (7.1 %). No additional grade 3 or above adverse events occurred. CONCLUSION:Preliminary results suggest that RS is a feasible treatment option for secondary liver tumors > 3 cm with few major adverse events.

    2026European journal of radiology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Final Outcomes of the SOFT and TEXT Phase III Trials in Premenopausal Hormone Receptor-Positive Early Breast Cancer.
    P A Francis, O Pagani, G F Fleming, B A Walley, M Colleoni, G Rubovszky, C Tondini, E M Ciruelos, H L Gomez, H R Bonnefoi, H J Burstein, C Chini,

    BACKGROUND:The Suppression of Ovarian Function Trial (SOFT) found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. A combined analysis of SOFT and TEXT showed a significant reduction in distant recurrence with E+OFS versus T+OFS. We now report final 15-year outcomes. PATIENTS AND METHODS:Premenopausal women with hormone receptor-positive early breast cancer were enrolled, with 3047 in SOFT and 2660 in TEXT intention-to-treat populations. SOFT randomized to 5 years of T versus T+OFS versus E+OFS. TEXT randomized to 5 years of T+OFS versus E+OFS. Chemotherapy was optional, before SOFT entry with subsequent premenopausal oestradiol or concurrent with OFS in TEXT. Endpoints included disease-free survival, breast cancer-free interval (BCFI), distant recurrence-free interval (DRFI), and overall survival (OS). Additionally, 15-year Kaplan-Meier estimates, hazard ratios (HRs), and 95% confidence intervals (CIs) are reported. RESULTS:In SOFT, escalating endocrine therapy (ET) continued to reduce recurrence with 15-year BCFI of 78.6% for E+OFS, 75.7% for T+OFS, and 72.1% for T (T+OFS versus T: HR 0.82, 95% CI, 0.69-0.98, P = 0.03). In the SOFT no-chemotherapy cohort, OFS reduced breast cancer events at 15 years, while DRFI and OS remained high regardless of ET assignment. After prior chemotherapy for HER2-negative tumors (n = 1257), the 15-year OS rate in SOFT was 81.0% with E+OFS, 77.1% with T+OFS and 76.8% with tamoxifen alone. In women under age 35 years with HER2-negative tumors (n = 241), the 15-year OS rate was 82.5% with E+OFS, 77.9% with T+OFS, and 68.1% with tamoxifen. In combined SOFT and TEXT analysis, among those with HER2-negative tumors (n = 4035), E+OFS versus T+OFS reduced distant recurrence (HR 0.75, 95% CI 0.63-0.90), with a smaller reduction in deaths (HR 0.89, 95% CI 0.74-1.06), with absolute survival benefits largest with high-risk features, particularly young age or high-grade tumors. CONCLUSION:Meaningful OS benefit in hormone receptor-positive, HER2-negative breast cancer from adjuvant exemestane and/or OFS compared with tamoxifen alone is limited to high-risk premenopausal subgroups. Tamoxifen-based ET may not result in optimal outcomes in premenopausal high-grade HER2-negative tumors.

    2026Annals of oncology official journal of the European Society for Medical Oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4From Opinions to Outcomes: Optimizing Survey Methods and Principles Applicable to the Delphi Process in Critical Care Research
    Deepa Ramadurai,Vitaly Herasevich,Scott Bolesta,Gretchen M Brophy, Deyin Doreen Hsing, Philippe R Bauer, Pooja Amar Nawathe,Robert MacLaren,Ashish K Khanna,C Jessica Dine

    BACKGROUND. Survey research in critical care has dramatically increased over the past 25 years, and use of surveys within Delphi methods, which provide consensus definitions for heterogeneous disease states, has similarly expanded significantly. It is crucial for survey researchers to understand the nuances of survey development and expectations of information provided by surveys, to use them correctly. Few simple sources exist to guide development considerations to generate high-quality survey research. No studies to our knowledge exist that draw parallels between the principles of survey research as a guide within the Delphi process, as one potential conduit between a steering committee and expert panel. METHODS. We present a narrative review of and framework for rigorous design of survey research, highlighting the applicability to the design of surveys administered within Delphi methods. RESULTS AND CONCLUSIONS. The methodologic considerations presented for survey research and Delphi methods can inform high-quality critical care research.

    2026Critical care explorations(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5American Society of Hematology 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
    Adam S DuVall,Jennifer McNeer,Matthew C Cheung, Diego A Adrianzen-Herrera,Anjali Advani,Mahmoud Aljurf,Anthony Audino,Lydia Benitez, Anastasia Deeter,Emily Dworkin, Olivia Hiltbrand,Leidy Isenalumhe,

    BACKGROUND:Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) represent a unique population. Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting. They also have distinctive care needs, social risk factors, and disease behavior compared with other age groups. OBJECTIVE:These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the frontline management of ALL in AYAs. METHODS:ASH formed a multidisciplinary guideline panel including hematologists, AYA psychosocial care specialists, pharmacists, methodologists, and patient representatives with efforts to minimize bias from conflicts of interest. An evidence review team at Brown University supported guideline development, including performing systematic evidence reviews up to November 2023. The panel prioritized clinical questions and outcomes according to importance for clinicians and patients. The panel used grading of recommendations assessment, development, and evaluation (GRADE), including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS:The panel agreed on 15 recommendations and several good practice statements. CONCLUSIONS:Pediatric-inspired regimens containing asparaginase are recommended as frontline therapy compared with more traditional adult-inspired protocols, requiring significant supportive care and close follow-up. Allogeneic hematopoietic stem cell transplantation is not routinely recommended in first remission but may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy. The use of targeted agents in frontline therapy is increasingly supported, although further research is needed to optimize this strategy.

    2026Blood advances(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2859 篇论文

    合作机构(100)

    芝加哥大学合作论文 598
    华盛顿大学合作论文 77
    温纳贝戈医学中心合作论文 74
    丹娜—法伯癌症研究所合作论文 72
    普利兹克医学院合作论文 72
    纪念斯隆凯特琳癌症中心合作论文 72
    德克萨斯大学奥斯汀分校合作论文 63
    宾夕法尼亚大学合作论文 63
    Massachusetts General Hospital,Harvard Medical School合作论文 56
    密歇根大学合作论文 50

    机构统计